Lubris, LLC, is dedicated to the development and commercialization of LUB-013, a proprietary recombinant form of the human protein Lubricin to treat a wide variety of age and inflammation related conditions, including osteoarthritis, dry eye disease, dry mouth, and women's health.
Lubricin is the primary human protein responsible for providing lubrication at tissue interfaces throughout the body, including the joint and the eye. Lubris is developing a recombinant form of this protein, LUB-013, that is capable of restoring lubrication to tissue surfaces in need.
Dry eye is a condition in which a patient has insufficient tear quantity or quality to lubricate and nourish the eye. An estimated 25 million people in the US are affected. Supplementation with LUB-013 may be an effective approach to disease management.
About 27 million Americans are living with Osteoarthritis, the most common form of joint disease. With OA, the articular cartilage that covers the ends of bones in the joints gradually wears away. Lubricin is known to protect the surface of cartilage from degeneration and supplementation with LUB-013 may help to reduce pain associated with OA.